Table 1 Kinase inhibition profile of ABT-869 (with permission adapted from Molecular Cancer Therapeutics 2006;5:995–1006)
From: ABT-869, a promising multi-targeted tyrosine kinase inhibitor: from bench to bedside
Related RTKa | Non-related TKa | Ser/Thr Kinasesb | |||
|---|---|---|---|---|---|
Kinase | IC50 (nM) | Kinase | IC50 (nM) | Kinase | IC50 (nM) |
KDR | 8 | SRC | > 50,000 | AKT | > 50,000 |
FLT1 | 3 | IGFR | > 50,000 | SGK | 940 |
FLT4 | 40 | INSR | > 50,000 | CDC2 | 9,800 |
PDGFRα | 29 | LCK | 38,000 | PKA | 5,900 |
PDGFRβ | 25 | EGFR | > 50,000 |  |  |
CSF-1R | 5 | HCK | > 50,000 | Â | Â |
KIT | 20 | CMET | > 50,000 | Â | Â |
FLT3 | 10 | LYN | > 20,000 | Â | Â |
TIE2 | 170 | FYN | > 50,000 | Â | Â |
RET | 1,900 | FGR | > 50,000 | Â | Â |
FGFR | > 12,500 | Â | Â | Â | Â |